GLAUKOS CORP
GKOSNYSETrading Snapshot
- Day Range
- $174.75 – $187.92
- 52-Week Range
- $73.16 – $191.62
- Volume (shares)
- 1,879,893
- Avg Volume (shares)
- —
- Shares Outstanding
- 59.0M
- Next Earnings
- 2026-10-28
Fundamentals Snapshot
- Annual Revenue
- $507M
- Last Q Revenue
- $186M
- P/E Ratio
- —
- P/S Ratio
- 17.2x
- EPS (TTM)
- $-3.26
- Dividend Yield
- —
- Dilution (1yr)
- +3.5%
GLAUKOS CORP
GKOS
StockOtter · stockotter.spaceAbout GLAUKOS CORP
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Glaukos Q3 Earnings Call Highlights
Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The compan
State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOS
State of Alaska Department of Revenue lowered its stake in Glaukos Corporation (NYSE: GKOS) by 48.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor own
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Glaukos: The Second J-Code Rewrites The Risk Math
Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.